Clinical trial
Treatment of Childhood Acute Lymphoblastic Leukemia
NCT00165087 · Dana-Farber Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00165087 |
|---|---|
| Title | Treatment of Childhood Acute Lymphoblastic Leukemia |
| Official title | Treatment of Childhood Acute Lymphoblastic Leukemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Boston Children's Hospital |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Lymphoblastic Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | asparaginase (E. Coli), asparaginase (Erwina), dexrazoxane, doxorubicin, cranial radiation (once daily fractionation), cranial radiation (twice-daily fractionation), Intrathecal chemotherapy without radiation |
| Enrollment | 491 |
| Start date | Jan 1, 1996 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Sep 14, 2005 |
| Last update posted | Dec 28, 2007 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: